NO20091595L - Liposomal gel ftalocyanin fremgangsmate for fotodynamisk terapi av svulster og fremstilling derav - Google Patents

Liposomal gel ftalocyanin fremgangsmate for fotodynamisk terapi av svulster og fremstilling derav

Info

Publication number
NO20091595L
NO20091595L NO20091595A NO20091595A NO20091595L NO 20091595 L NO20091595 L NO 20091595L NO 20091595 A NO20091595 A NO 20091595A NO 20091595 A NO20091595 A NO 20091595A NO 20091595 L NO20091595 L NO 20091595L
Authority
NO
Norway
Prior art keywords
phthalocyanine
hydrophobic
tumors
preparation
liposomes
Prior art date
Application number
NO20091595A
Other languages
English (en)
Norwegian (no)
Inventor
Petr Jezek
Milos Nekvasil
Pavla Pouckova
Original Assignee
Rcd Sro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rcd Sro filed Critical Rcd Sro
Publication of NO20091595L publication Critical patent/NO20091595L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20091595A 2006-11-28 2009-04-22 Liposomal gel ftalocyanin fremgangsmate for fotodynamisk terapi av svulster og fremstilling derav NO20091595L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20060743A CZ2006743A3 (cs) 2006-11-28 2006-11-28 Liposomální gelový ftalocyaninový prípravek pro fotodynamickou terapii nádorových onemocnení a zpusob jeho prípravy
PCT/CZ2007/000107 WO2008074267A2 (en) 2006-11-28 2007-11-27 Liposomal gel phthalocyanine preparation for photodynamic therapy of tumors and its manufacturing

Publications (1)

Publication Number Publication Date
NO20091595L true NO20091595L (no) 2009-06-26

Family

ID=39198233

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091595A NO20091595L (no) 2006-11-28 2009-04-22 Liposomal gel ftalocyanin fremgangsmate for fotodynamisk terapi av svulster og fremstilling derav

Country Status (6)

Country Link
US (1) US20100055165A1 (cs)
EP (1) EP2101732B1 (cs)
CA (1) CA2665762C (cs)
CZ (1) CZ2006743A3 (cs)
NO (1) NO20091595L (cs)
WO (1) WO2008074267A2 (cs)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101118586B1 (ko) * 2009-04-15 2012-02-27 포항공과대학교 산학협력단 고분자 캡슐을 포함하는 광역학 치료용 조성물
WO2015026963A2 (en) * 2013-08-21 2015-02-26 Oregon State University Phthalocy anine-dendrimer compositions and a method of using
CZ2017657A3 (cs) * 2017-10-16 2018-12-19 Fyziologický ústav AV ČR, v. v. i. Liposomová léková forma se světlo-konvertujícími nanočásticemi, její příprava a použití

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466468A (en) * 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US20030194376A1 (en) * 1990-05-18 2003-10-16 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US5616602A (en) * 1993-07-09 1997-04-01 Ciba-Geigy Corporation Topically administrable zinc phthalocyanine compositions
FR2714621B1 (fr) * 1994-01-06 1996-02-23 Centre Nat Rech Scient Procédé de préparation de liposomes sans utilisation de solvant organique.
GB9500116D0 (en) * 1995-01-05 1995-03-01 Ciba Geigy Ag Pharmaceutical compositions
US6176842B1 (en) * 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
US6492420B2 (en) * 1995-03-10 2002-12-10 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US6375930B2 (en) * 1996-06-04 2002-04-23 Board Of Regents, The University Of Texas System Membrane incorporation of texaphyrins
GB0005855D0 (en) * 2000-03-10 2000-05-03 Scotia Holdings Plc Compounds for pdt
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
GB0312309D0 (en) * 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome
NZ543635A (en) * 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy
CA2540621A1 (en) * 2003-11-19 2005-06-09 Barnes-Jewish Hospital Enhanced drug delivery
EP1547581A1 (en) * 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
JP4970424B2 (ja) * 2005-03-28 2012-07-04 リゲロン アイエヌシー 蛋白質を包囲するナノリポソームの製造方法及び蛋白質−包囲ナノリポソーム

Also Published As

Publication number Publication date
US20100055165A1 (en) 2010-03-04
CA2665762C (en) 2013-02-05
EP2101732A2 (en) 2009-09-23
WO2008074267A2 (en) 2008-06-26
CZ298978B6 (cs) 2008-03-26
WO2008074267A3 (en) 2008-08-07
CZ2006743A3 (cs) 2008-03-26
CA2665762A1 (en) 2008-06-26
EP2101732B1 (en) 2019-05-29

Similar Documents

Publication Publication Date Title
NO20090598L (no) 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
BR122017016940B8 (pt) método para preparação de uma composição farmacêutica compreendendo alfa-galactosidase a
NO20055496L (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
RU2009128179A (ru) Наноэмульсия
CA2690111A1 (en) Anthelmintic combination
HRP20050712A2 (en) SUBSTITUTED HEXAHYDROPYRAZINO[1,2-a]PYRIMIDIN-4,7-DION DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS
MX2010009414A (es) Derivados de imidazo-[1,2-b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met.
WO2007105015A3 (en) DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID
WO2003082078A3 (en) Method and compositions for the diagnosis and treatment of non-small cell lung cancer using gene expression profiles
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
BRPI0411868B8 (pt) derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase
WO2008056368A3 (en) Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
EA201001241A1 (ru) Спирогетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
WO2008138348A8 (en) Preparation of complexed lactalbumin
CN108030773A (zh) 一种癌细胞膜包裹的负载自噬抑制剂的中空介孔二氧化钛仿生药物复合物的制备方法及应用
MY150408A (en) P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-ß-D-RIBOFURANOSYL)-3H-THIAZOLE[4,5-D]PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION
UY31588A1 (es) Derivados de imidazo[1,2-a]piridin-2-carboxamidas, su preparacion y su aplicacion en terapéutica
WO2007015171A3 (en) Method of treating patients with a mucinous glycoprotein (muc-1) vaccine
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение
MX2009004295A (es) Uso de un acido indazolmetoxialcanoico para reducir niveles de triglicerido, colesterol y glucosa.
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
Liu et al. Atomic artificial enzyme for acute and chronic Pneumonia
UY31587A1 (es) Derivados de n-heterociclico-imidazo[1,2-a]piridina-2-carboxamidas, su preparacion y su aplicacion en terapéutica.
BRPI0513287A (pt) derivados de pirido-pirimidina, sua preparação, sua aplicação em terapêutica

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: INSTITUTE OF PHYSIOLOGY OF AS CR VVI, CZ

FC2A Withdrawal, rejection or dismissal of laid open patent application